Dynavax Technologies Corp.

NASDAQ:DVAX   3:59:58 PM EDT
9.53
+0.14 (+1.49%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)1.08B
Current PEN/A
Forward PE 16.15
2yr Forward PE 45.38
See more stats
Estimates Current Quarter
Revenue$59.11 Million
Adjusted EPS-$0.03
See more estimates
10-Day MA$9.92
50-Day MA$9.65
200-Day MA$6.83
See more pivots

Dynavax Technologies Corp. Stock, NASDAQ:DVAX

2100 Powell Street, Suite 900, Emeryville, California 94608
United States of America
Phone: +1.510.848.5100
Number of Employees: 245

Description

Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Berkeley, CA.